查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
虛擬臨床試驗全球市場研究報告——2023-2030 年行業分析、規模、研究、增長、趨勢和預測
市場調查報告書
商品編碼
1267304

虛擬臨床試驗全球市場研究報告——2023-2030 年行業分析、規模、研究、增長、趨勢和預測

Global Virtual Clinical Trials Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

全球對虛擬臨床試驗市場的需求將從 2022 年的 122.4 億美元增長到 2030 年的近 261.2 億美元，在 2023 年至 2030 年的研究期間預計將達到 9.94% 的複合年增長率。

虛擬臨床試驗是由技術推動的臨床試驗技術。 虛擬方法使您可以在家參加臨床試驗，並在來訪困難時繼續學習。 因此，我們可以提供創新工具來收集臨床試驗參與者的安全性和有效性信息。 這些解決方案在技術、高級軟件、小工具、在線社交網站、機器人過程自動化、機器學習等方面具有無數優勢。 這些虛擬臨床試驗方便、實惠且以患者為中心。

市場力量：

虛擬臨床試驗正變得越來越流行和發展，因為它們更舒適、以患者為中心且更具成本效益。 政府提高公眾意識的努力也在推動虛擬臨床試驗市場的發展。 隨著對用於臨床目的的實用、省時、簡單和安全平台的需求增加，這些試驗的市場規模也有望增長。 隨著許多製造商資助研發，市場也在擴大。 然而，公眾認知度低可能會阻礙虛擬臨床試驗市場的擴張。

這份研究報告描述了波特的五力模型、市場吸引力分析和價值鏈分析。 這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。 此外，這些工具還對全球虛擬臨床試驗市場的每個細分市場進行全面評估。 虛擬臨床試驗行業的發展和趨勢為這項研究提供了一種整體方法。

市場細分：

本部分提供有關國家和地區細分的詳細數據，以幫助戰略制定者確定各自產品和服務的目標受眾，並幫助他們把握未來的商機。

通過研究設計

  • 干預
  • 觀察類型
  • 擴大訪問範圍

通過顯示

  • 中樞神經系統
  • 自身免疫/炎症
  • 心血管疾病
  • 代謝/內分泌學
  • 感染
  • 腫瘤學
  • 泌尿系統
  • 眼科
  • 其他

按階段

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

按地區分析：

本部分介紹了區域前景，重點關注北美、歐洲、亞太地區、拉丁美洲、中東和非洲虛擬臨床試驗市場當前和未來的需求。 此外，我們還關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。 虛擬臨床試驗市場的主要參與者有 ICON PLC、Parexel International Corporation、IQVIA、Covance、PRA Health Sciences、LEO Innovation Lab、Medidata、Oracle、CRF Health、Clinical Ink、Medable Inc、Clinical Ink、Halo Health Systems、Croprime 等。是。 本節包括對競爭格局的全面了解，包括各種戰略發展，例如主要併購、未來能力、合作夥伴關係、財務概覽、合作、新產品開發和新產品發布。

內容

第一章前言

  • 報告內容
    • 目的
    • 目標受眾
    • USP（獨特的銷售建議）及其提供的內容
  • 調查範圍
  • 調查方法
    • 市場調研流程
    • 市場研究方法

第 2 章執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章虛擬臨床試驗 - 行業分析

  • 簡介 - 市場動態
  • 市場驅動力
  • 市場製約因素
  • 機會
  • 行業趨勢
  • 波特的五力分析
  • 市場吸引力分析
    • 通過研究設計進行市場吸引力分析
    • 按適應症分類的市場吸引力分析
    • 按階段分析市場吸引力
    • 市場吸引力分析：按地區

第四章價值鏈分析

  • 價值鏈分析
  • 原材料分析
    • 原材料清單
    • 原材料製造商列表
    • 主要原材料價格走勢
  • 潛在買家名單
  • 營銷渠道
    • 直接營銷
    • 間接營銷
    • 市場發展趨勢

第 5 章 COVID-19 爆發的影響分析

第 6 章虛擬臨床試驗的全球市場分析：按研究設計

  • 按研究設計總結
  • 過去和未來的數據
  • 研究設計分析
  • 干預
  • 觀察類型
  • 擴大訪問範圍

第 7 章虛擬臨床試驗的全球市場分析：按適應症

  • 功效概述
  • 過去和未來的數據
  • 適應症分析
  • 中樞神經系統
  • 自身免疫/炎症
  • 心血管疾病
  • 代謝/內分泌學
  • 感染
  • 腫瘤學
  • 泌尿系統
  • 眼科
  • 其他

第 8 章虛擬臨床試驗的全球市場銷售分析：按階段

  • 階段大綱
  • 過去和未來的數據
  • 階段分析
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第 9 章虛擬臨床試驗的全球市場銷售分析：按地區

  • 按地區進行的銷售前景分析
  • 介紹銷售分析
  • 北美銷售分析
    • 概覽、歷史和預測銷售分析
    • 北美各部門的銷售分析
    • 北美銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史和預測銷售分析
    • 按細分市場進行的歐洲銷售分析
    • 按國家/地區劃分的歐洲銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 意大利銷售分析
    • 俄羅斯銷售分析
    • 其他歐洲銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史和預測銷售分析
    • 亞太地區各部門的銷售分析
    • 亞太國家/地區銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本的銷售分析
    • 韓國銷售分析
    • 澳大利亞銷售分析
    • 其他亞太地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史和預測銷售分析
    • 拉丁美洲各部門的銷售分析
    • 拉丁美洲國家/地區的銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利的銷售分析
    • 其他拉丁美洲銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史和預測銷售分析
    • 中東和非洲各細分市場的銷售額分析
    • 中東和非洲國家/地區的銷售分析
    • 沙特阿拉伯銷售分析
    • 阿聯酋銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 其他中東和非洲銷售分析

第10章虛擬臨床試驗公司的競爭格局

  • 虛擬臨床試驗市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他擴展

第11章公司簡介

  • 前 10 名公司的市場份額分析
  • 市場集中度
  • 圖標PLC
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • Parexel 國際公司
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • 艾昆緯
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • 科文斯
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • PRA 健康科學
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • LEO 創新實驗室
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • Medidata
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • 甲骨文
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • CRF 健康
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • 臨床墨水
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • 醫療公司
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • 臨床墨水
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • Halo 健康系統
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢
  • 克羅普萊姆
    • 公司概況
    • 企業收入
    • 產品介紹
    • 近期趨勢

注意：公司簡介中的財務信息和近期發展基於可用信息，可能不涵蓋私營公司。

Product Code: VMR11219982

The global demand for Virtual Clinical Trials Market is presumed to reach the market size of nearly USD 26.12 BN by 2030 from USD 12.24 BN in 2022 with a CAGR of 9.94% under the study period 2023 - 2030.

A virtual clinical trial refers to clinical trial techniques facilitated by technology. A virtual approach enables individuals to participate in the trial from the convenience of their homes, ensuring that research may continue even when site visits are inconvenient. As a result, it provides an innovative tool for gathering safety and efficacy information from clinical study participants. These solutions consider the countless advantages of technology, advanced software, gadgets, online social networking sites, robotic process automation, machine learning, and others. These virtual clinical trials are convenient, affordable, and patient-focused.

Market Dynamics:

The virtual clinical trial approach is more comfortable, patient-centered, and cost-effective, so virtual trials are becoming more popular and are growing. The government's attempt to increase public awareness also assists in the market expansion of virtual clinical trials. As the demand for a practical, time-saving, easy, safe platform for clinical purposes grows, so does the market for these trials is expected to scale up. Moreover, the market is growing since a lot of manufacturers are funding R&D initiatives. However,lack of public awareness may hamper the expansion of the virtual clinical trial market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of virtual clinical trials. The growth and trends of virtual clinical trials industry provide a holistic approach to this study.

Market Segmentation:

This section of the virtual clinical trials market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Study Design

  • Interventional
  • Observational
  • Expanded Access

By Indication

  • CNS
  • Autoimmune/Inflammation
  • Cardiovascular Disease
  • Metabolic/Endocrinology
  • Infectious Disease
  • Oncology
  • Genitourinary
  • Ophthalmology
  • Others

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase Iv

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Virtual Clinical Trials market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the virtual clinical trials market include ICON PLC, Parexel International Corporation, IQVIA, Covance, PRA Health Sciences, LEO Innovation Lab, Medidata, Oracle, CRF Health, Clinical Ink, Medable Inc, Clinical Ink, Halo Health Systems, Croprime. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . VIRTUAL CLINICAL TRIALS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Study Design
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Phase
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL VIRTUAL CLINICAL TRIALS MARKET ANALYSIS BY STUDY DESIGN

  • 6.1 Overview by Study Design
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Study Design
  • 6.4 Interventional Historic and Forecast Sales by Regions
  • 6.5 Observational Historic and Forecast Sales by Regions
  • 6.6 Expanded Access Historic and Forecast Sales by Regions

7 . GLOBAL VIRTUAL CLINICAL TRIALS MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 CNS Historic and Forecast Sales by Regions
  • 7.5 Autoimmune/Inflammation Historic and Forecast Sales by Regions
  • 7.6 Cardiovascular Disease Historic and Forecast Sales by Regions
  • 7.7 Metabolic/Endocrinology Historic and Forecast Sales by Regions
  • 7.8 Infectious Disease Historic and Forecast Sales by Regions
  • 7.9 Oncology Historic and Forecast Sales by Regions
  • 7.10. Genitourinary Historic and Forecast Sales by Regions
  • 7.11 Ophthalmology Historic and Forecast Sales by Regions
  • 7.12 Others Historic and Forecast Sales by Regions

8 . GLOBAL VIRTUAL CLINICAL TRIALS MARKET SALES ANALYSIS BY PHASE

  • 8.1 Overview by Phase
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Phase
  • 8.4 Phase I Historic and Forecast Sales by Regions
  • 8.5 Phase II Historic and Forecast Sales by Regions
  • 8.6 Phase III Historic and Forecast Sales by Regions
  • 8.7 Phase IV Historic and Forecast Sales by Regions

9 . GLOBAL VIRTUAL CLINICAL TRIALS MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE VIRTUAL CLINICAL TRIALS COMPANIES

  • 10.1. Virtual Clinical Trials Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF VIRTUAL CLINICAL TRIALS INDUSTRY

  • 11.1. Top 10 Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. ICON PLC
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Parexel International Corporation
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. IQVIA
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. Covance
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. PRA Health Sciences
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. LEO Innovation Lab
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Medidata
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Oracle
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. CRF Health
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Clinical Ink
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Medable Inc
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Clinical Ink
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments
  • 11.15. Halo Health Systems
    • 11.15.1. Company Overview
    • 11.15.2. Company Revenue
    • 11.15.3. Products
    • 11.15.4. Recent Developments
  • 11.16. Croprime
    • 11.16.1. Company Overview
    • 11.16.2. Company Revenue
    • 11.16.3. Products
    • 11.16.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Study Design (USD MN)
  • Interventional Market Sales by Geography (USD MN)
  • Observational Market Sales by Geography (USD MN)
  • Expanded Access Market Sales by Geography (USD MN)
  • Analysis Market by Indication (USD MN)
  • CNS Market Sales by Geography (USD MN)
  • Autoimmune/Inflammation Market Sales by Geography (USD MN)
  • Cardiovascular Disease Market Sales by Geography (USD MN)
  • Metabolic/Endocrinology Market Sales by Geography (USD MN)
  • Infectious Disease Market Sales by Geography (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Genitourinary Market Sales by Geography (USD MN)
  • Ophthalmology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Phase (USD MN)
  • Phase I Market Sales by Geography (USD MN)
  • Phase II Market Sales by Geography (USD MN)
  • Phase III Market Sales by Geography (USD MN)
  • Phase IV Market Sales by Geography (USD MN)
  • Global Virtual Clinical Trials Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Virtual Clinical Trials Report
  • Market Research Process
  • Market Research Methodology
  • Global Virtual Clinical Trials Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Study Design
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Phase
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Study Design (USD MN)
  • Interventional Market Sales by Geography (USD MN)
  • Observational Market Sales by Geography (USD MN)
  • Expanded Access Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • CNS Market Sales by Geography (USD MN)
  • Autoimmune/Inflammation Market Sales by Geography (USD MN)
  • Cardiovascular Disease Market Sales by Geography (USD MN)
  • Metabolic/Endocrinology Market Sales by Geography (USD MN)
  • Infectious Disease Market Sales by Geography (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Genitourinary Market Sales by Geography (USD MN)
  • Ophthalmology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Phase (USD MN)
  • Phase I Market Sales by Geography (USD MN)
  • Phase II Market Sales by Geography (USD MN)
  • Phase III Market Sales by Geography (USD MN)
  • Phase IV Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.